To study the role of toll-like receptor 4 (TLR4) and 
| INTRODUCTION
Inflammation is crucial for the initiation and progression of atherosclerosis from the initial lesions to end-stage complications, participating in the progression of a stable plaque to a vulnerable one, which leads to acute coronary syndrome (ACS). Toll-like receptor 4 (TLR4) is an innate immune receptor expressed in immune cells and the heart that plays an important role in promoting atherosclerosis by expressing inflammatory proteins.
1,2 TLR4 signaling is closely related to plaque destabilization. MicroRNA-155 (miR-155), a typical multi-functional miRNA, has recently emerged as a novel component of inflammatory signal transduction in the pathogenesis of atherosclerosis and the onset of ACS. 3 However, the mechanisms by which miR-155 functions as a putative pro-instability plaque microRNA are largely unknown.
The coronary slow flow (CSF) phenomenon is not a rare finding, and CSF is characterized by angiographically normal or near-normal coronary arteries with delayed distal angiogram. Sometimes only according to clinical symptoms, it can be difficult to distinguish CSF from ACS, and therefore, we propose that the underlying pathological mechanisms for these conditions are related. Possible underlying mechanisms of CSF are endothelial dysfunction, chronic inflammation, microvascular dysfunction, and diffuse atherosclerosis. However, little is known about the inflammatory reaction and the role of PBMCsexpressed TLR4 and miR-155 in CSF patients. Therefore, this study
| Separation of PBMCs and treatment groups
Twenty milliliters of whole blood was collected from each potential participant into sodium citrate anticoagulation tubes and then separated the peripheral blood mononuclear cells (PBMCs) using Lymphocyte Separation Medium (Solarbio Beijing Biotechnology Co., Ltd., Beijing, China). PBMCs was stored at −80°C until further analysis.
Prior to intervention, the levels of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-1, and IL-10 in plasma as well as the expression of TLR4 and miR-155 on PBMCs were detected, as described below. 
| Recombinant adenoviral antagomiR-155 over-expression

| Enzyme-linked immunosorbent assay (ELISA)
Peripheral blood mononuclear cells ( 1×10 6 ) were plated into 24-well plates, and after 24 hours in culture in RPMI 1640 culture medium containing 10% calf serum (both from Beijing TransGen Biotech, Beijing, China), the cells were incubated with LPS/and Ad-antagoniR-155
as described above. The concentrations of TNF-α, IL-1, IL-6, and IL-10 in the collected media samples were detected using commercial sandwich ELISA kits (Boster Wuhan Biotechnology Co., Ltd., Wuhan, China) according to the manufacturer's instructions.
| Flow cytometric analysis
Flow cytometric analysis was performed according to standard procedures. Briefly, 100 μL aliquots of cells were stained with 5 μL phycoerythrin-labeled mice anti-human TLR4 monoclonal antibody (eBioscience, San Diego, CA, USA) at 37°C for 30 minutes in the dark and then washed twice with 1% phosphate-buffered saline (PBS). After centrifugation (1500 g for 3 minutes at 4°C), the cells were resuspended in 300 μL of 1% PBS. Cells were analyzed using a flow cytometer (Beckman Coulter, Miami, FL, USA).
| Quantitative real-time reverse transcriptionpolymerase chain reaction
RNA was isolated from cultured cells using Trizol-based methods, and then reverse transcribed into cDNA. MiR-155 upstream primer: 5′-GGAGGTTAATGCTAATCG TGATAG-3′ downstream primer: 5′-GTGCAGGGTCCGAGGT-3′. U6 upstream primer:
5′-CTCGCTTCGGCAGCACA-3′, downstream primer: 5′-AACGCTTCA CGAATTTGCGT-3′. Conditions for qRT-PCR were as follows: In the first cycle, reagent mixes were incubated at 95°C for 10 minutes, then at 95°C for 15 seconds, and finally at 60°C for 60 seconds. This cycle was repeated 40 times. The internal normalized reference was U6
snRNA. The relative expression values of miR-155 in each group were calculated using the 2 −ΔΔCt method. 
| Statistical analysis
| RESULTS
| Clinical characteristics of the patients
The baseline demographic and clinical characteristics of the patients are summarized in Table 1 . No significant differences were observed in patient age, gender, smoking status, alcohol consumption, body mass index (BMI), and waist circumference among the four groups. In addition, the frequencies of dyslipidemia and hypertension did not differ significantly among the ACS, SAP, and CSF groups ( Table 1) .
| TLR4 and miR-155 expression and inflammatory cytokine secretion before intervention
Toll-like receptor 4 expression was significantly higher in PBMCs from the ACS group compared with those from the SAP, CSF, and HC groups prior to intervention ( Table 2 ). The level of miR-155 was lower in patients with ACS group than in patients with other three groups (Table 3) . No significant differences in TLR4 and miR-155 expression were observed among the SAP, CSF, and HC groups (Tables 2 and   3 ). The level of TNF-α, IL-1, and IL-6 were significantly higher in the ACS group compared with those in the SAP, CSF, and HC groups prior to intervention. In addition, the level of IL-10 was lower in the ACS group than in the other three groups. The level of TNF-α, IL-1, IL-6, and IL-10 did not differ significantly among the SAP, CSF, and HC groups ( Table 2 ).
| TLR4 and miR-155 expression and inflammatory cytokine secretion after LPS stimulation
After in vitro stimulation of the PBMCs of the SAP, CSF, and HC groups with LPS, TLR4 expression, miR-155 expression, and the concentra- 
| Inflammatory cytokine secretion after Ad-antagomiR-155 pre-treatment
Peripheral blood mononuclear cells in the SAP and CSF groups were pre-treated with antagomiR-155 for 2 hours, then treated with LPS IL-1, and IL-6 were significantly higher and that of IL-10 was significantly lower in the ACS group compared with the SAP, CSF, and HC
groups.
Although some research have focused on microRNA-155 as an atherosclerosis regulator, the pro-atherosclerosis mechanisms are largely unknown. Circulating levels of miR-155 are significantly downregulated in patients with coronary artery disease compared with healthy controls. 15 The expression of miR-155 in the PBMCs of ACS patients was decreased by approximately 60%, showed no significant difference between unstable angina group and chest pain syndrome group. 16 In vitro experiments confirmed that miR-155 expression in macrophages was increased in response to LPS stimulation. 17 The results of the present study also confirmed that the level of miR-155 was significantly lower in the ACS group.
Plaque rupture has been shown to be a major contributing factor in the initiation of the occurrence of ACS. 18 Notably, increased levels of inflammatory cytokines are associated with plaque rupture.
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TLR4 expressions of PBMCs and plaque debris from ACS patients was significantly higher than those from SAP patients. The mechanism of the CSF phenomenon may be closely associated with inflammation, 25, 26 with one study even proposing it may be the early phenomenon in coronary atherosclerosis. 27 Previous studies have reported that the levels of inflammatory markers may be associated with pathogenesis of CSF. 26, 28 Here, we also found that the TNF-α, IL-1, and IL-6 levels were slightly higher for the CSF group compared T A B L E 4 Toll-like receptor 4 expression and inflammatory cytokine concentrations after LPS stimulation T A B L E 5 Inflammatory cytokine concentrations after AdantagomiR-155 pre-treatment with the HC group and were comparable to those of the SAP group.
When the PBMCs of CSF group were treated with LPS or with overexpressing antagomiR-155 and LPS, the level of TLR4, miR-155 and inflammatory reaction were the same as those of SAP group. Therefore, no matter the findings of previous studies or our study all strengthen the hypothesis that the CSF phenomenon was closely linked to the inflammatory response, CSF represented a potential form of "ACS", with the same clinical importance as SAP.
Our results further illustrate that inflammation is a key factor in the onset of ACS, miR-155 can induce the expression of the proinflammatory cytokines in LPS-treated PBMCs. Effective inhibition of the inflammatory response by depressing miR-155 may represent a target for therapies to stabilize plaques and thus improve patients' clinical prognosis.
